Helio Genomics expanded commercialization for its HelioLiver blood-based liver cancer screening test by partnering with Syneos Health. The companies said the deal is intended to broaden adoption and reduce friction in provider engagement. HelioLiver is designed to detect hepatocellular carcinoma using AI-driven signals derived from cell-free DNA methylation patterns, protein biomarkers, and patient demographics. Helio said the partnership will leverage Syneos Health’s commercial execution capabilities while continuing earlier distribution steps, including co-branding with Fulgent Genetics and availability through Quest Diagnostics-affiliated providers. Helio’s CEO said the agreement “de-risks” broad market adoption by combining Helio’s technology with Syneos’ scale in commercial programs.